MiMedx Board Member Shows Confidence with 28,609 Share Acquisition

Rhea-AI Filing Summary

MiMedx Group director Tiffany Olson received an annual restricted stock grant of 28,609 shares on June 18, 2025, at a price of $6.47 per share. Following this transaction, Olson's direct ownership increased to 57,597 shares.

Key details of the grant:

• Transaction was filed as an exempt grant under Rule 16b-3
• Vesting occurs at the earlier of 12 months or next annual shareholder meeting
• Grant is part of standard non-employee director compensation
• Transaction was executed through attorney-in-fact William F. Hulse

This Form 4 filing represents routine board compensation and indicates continued alignment between director and shareholder interests through equity-based compensation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Olson Tiffany

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	28,609	$6.47	$185K

Holdings After Transaction: Common Stock — 57,597 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olson Tiffany

(Last) (First) (Middle)

1775 WEST OAK COMMONS CT NE

(Street)

MARIETTA GA 30062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		28,609(1)	A	$6.47	57,597	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders

Remarks:

	/s/ William F. Hulse as attorney-in-fact Tiffany Olson	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MDXG shares did Director Tiffany Olson acquire on June 18, 2025?

Director Tiffany Olson acquired 28,609 shares of MDXG common stock on June 18, 2025, as part of an annual restricted stock grant to non-employee directors at a price of $6.47 per share.

What is the vesting period for MDXG's director stock grants in 2025?

The restricted stock grant for MDXG non-employee directors vests upon the earlier of 12 months from the grant date or the next annual meeting of shareholders, as disclosed in the Form 4 filing.

How many MDXG shares does Tiffany Olson own after the June 2025 stock grant?

Following the reported transaction, Tiffany Olson directly owns 57,597 shares of MDXG common stock, as indicated in Table I of the Form 4 filing.

Was MDXG Director Tiffany Olson's stock acquisition made under Rule 10b5-1?

No, the stock acquisition was not made under Rule 10b5-1. The Form 4 indicates this was an annual restricted stock grant to non-employee directors that is exempt under Rule 16b-3.